摘要
目的探讨多西他赛联合希罗达治疗晚期胃癌的疗效及不良反应发生情况。方法将86例晚期胃癌患者回顾性分为多西他赛联合希罗达治疗组(多西他赛联合组)及奥沙利铂联合希罗达治疗组(奥沙利铂联合组),观察两组治疗的远近期疗效及毒副反应发生情况。结果多西他赛联合组和奥沙利铂联合组的有效率分别为65.1%、55.8%(P=0.049),两组不良反应主要为胃肠道反应和骨髓抑制(P>0.05);两组的无进展生存时间分别为6.5个月、6.7个月(P>0.05),1年生存率分别为40.1%、39.3%(P>0.05)。结论多西他赛联合希罗达治疗晚期胃癌的有效率优于奥沙利铂联合希罗达,但并不能显著提高患者的生存率。
Objective To evaluate the efficacy and toxicity of Docetaxel plus Xeloda in the treatment of late-staged gastric cancer. Methods From May 2009 to May 2011,86 patients with late-staged gastric cancer treated in our depart- merit were divided into two groups in a random way. One group was treated with Docetaxel plus Xeloda （ Docetaxel group） , the other group was treated with Oxaliplatin plus Xeloda （Oxaliplatin group）. Then compare the effecary and toxicity of the two groups. Results The efficient was 65.1% （28 cases） and 55.8% （24 cases） in the Docetaxel group and Oxaliplatin group respectively（P =0.049）. The main adverse reactions were gastrointestinal reactions and bone marrow transplant（P 〉 0.05）. And the median progression-free survival were 6.5 month and 6.7 month （ P 〉 0.05 ） ; 1 year survival rate were 40. 1% and 39.3% （P 〉 0.05） respectively. Conclusion Docetaxel plus Xeloda is a more effective treatment regiment for late-staged gastric cancer than Oxaliplatin plus Xeloda treatment regiment. But it may not increase the survival rate.
出处
《中南医学科学杂志》
CAS
2012年第6期585-587,共3页
Medical Science Journal of Central South China
